| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_540eec52930b35c22108814088f97cb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2382176588ed0ca2c3378273cfd21426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44b04a43890fa083d7cde1bcb5e8a946 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06N20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06N5-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06G7-58 |
| filingDate |
2012-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b416c45c8bc7a8c396e7ab6ceefed9f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b8ae38826e6003728c503b731332118 |
| publicationDate |
2013-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013028480-A1 |
| titleOfInvention |
Method of drug repositioning |
| abstract |
Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease- side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11075008-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11037684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110297839-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2986587-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103251954-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10016373-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9530095-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9536194-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10685741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10692588-B2 |
| priorityDate |
2011-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |